Format

Send to

Choose Destination
Am J Respir Crit Care Med. 2011 Nov 15;184(10):1107-13. doi: 10.1164/rccm.201106-0995PP. Epub 2011 Aug 25.

Tuberculosis drug development: ensuring people living with HIV are not left behind.

Author information

1
HIV/AIDS Division, San Francisco General Hospital, University of California, San Francisco, CA 94110, USA. aluetkemeyer@php.ucsf.edu

Abstract

An unprecedented number of new tuberculosis (TB) medications are currently in development, and there will be great pressure to deploy these new drugs among all populations after their efficacy is demonstrated. People living with HIV experience a large burden of TB and have a particularly pressing need for TB treatments that are shorter and less toxic. In addition, all people living with HIV now require antiretroviral therapy during TB treatment. A roadmap of the research, programmatic, and regulatory considerations includes the following: (1) inclusion of people living with HIV early in clinical trials for treatment and prevention using new TB medications, (2) prioritization of key studies of HIV-TB drug interactions and interactions between new TB agents, and (3) optimization of clinical trial infrastructure, laboratory capacity, and drug susceptibility testing.

PMID:
21868507
PMCID:
PMC3361323
DOI:
10.1164/rccm.201106-0995PP
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center